TG Therapeutics announced that its Phase 3 ENHANCE trial met its primary endpoint for a single-infusion Briumvi regimen [1, 3, 4].
The results could change how patients receive the treatment by reducing the number of clinic visits required for dosing. A shift to a single-infusion schedule offers greater convenience for patients while aiming to maintain the same efficacy and safety as the existing protocol [3, 4].
The current administration of Briumvi requires a two-dose schedule, with infusions delivered on Day 1 and Day 15 [3, 4]. The ENHANCE trial was designed to evaluate whether a single-infusion approach could replace this regimen without compromising the drug's performance [3, 4].
According to the topline results released on May 28, 2026, the single-infusion regimen achieved bioequivalent drug exposure compared to the standard two-dose schedule [1, 2]. This means the amount of the drug reaching the systemic circulation is consistent across both methods of delivery [3, 4].
TG Therapeutics, listed on the NASDAQ as TGTX, is pursuing this streamlined dosing to improve patient adherence and quality of life [1, 2]. By eliminating the second visit, the company seeks to lower the burden on both the healthcare system and the individuals receiving the therapy [3, 4].
The company said it did not provide specific numerical data regarding the exact levels of bioequivalence in the initial announcement, but confirmed that the primary endpoint was met [1, 3, 4].
“The ENHANCE trial demonstrated that a single-infusion Briumvi regimen achieved bioequivalent exposure to the standard two-dose schedule.”
The successful Phase 3 trial suggests that Briumvi can be administered more efficiently without losing therapeutic potency. If regulatory bodies approve this change, it would transition the drug from a multi-step initiation process to a more streamlined single-event process, potentially increasing the drug's competitiveness in the market by reducing patient and provider burden.
